Las Vegas — The hypertrophic cardiomyopathy treatment market across seven major markets reached $3.2 billion in 2025 and is expected to expand over the next decade as new targeted therapies advance through development, according to a report from DelveInsight.
The report covers the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. DelveInsight estimated about 11 million prevalent cases of hypertrophic cardiomyopathy, or HCM, across those markets in 2025.
The company said growth is expected to be driven by greater disease awareness, improved diagnosis and the emergence of therapies designed to target underlying disease mechanisms rather than only manage symptoms.
Among the experimental treatments highlighted in the report are sotagliflozin from Lexicon Pharmaceuticals, ninerafaxstat from Imbria Pharmaceuticals, EDG-7500 from Edgewise Therapeutics and TN-201 from Tenaya Therapeutics.
Sotagliflozin, a dual SGLT1/SGLT2 inhibitor, is being studied in both obstructive and non-obstructive HCM, with topline data from its clinical program expected in the first quarter of 2027. Ninerafaxstat is being evaluated in the Phase II FORTITUDE-HCM trial as a metabolism-focused treatment designed to improve cardiac efficiency.
Current treatment has historically relied on beta blockers, calcium channel blockers and other drugs aimed largely at symptom control and prevention of complications. More recently, cardiac myosin inhibitors such as mavacamten and aficamten have introduced disease-specific targeted treatment approaches.
DelveInsight said the pipeline remains active, with pharmaceutical and biotechnology companies investing in cardiac and metabolic therapies that could further reshape the HCM market over the coming years.
Recent developments cited in the report include positive Phase III results for aficamten in non-obstructive HCM and continued advancement of Lexicon Pharmaceuticals’ Phase III SONATA-HCM study of sotagliflozin.
